Patient First Name: Guido
Social aspects: Married, father of 2 sons. Active and highly engaged in the school community with a strong sense of responsibility. Organizer and tour guide for youth vacations
Patient expectations/wish: The patient has difficulties to accept the disease but has high hopes to be cured.
Tumor burden (size, disease-related symptoms): Obstructive sigmoid carcinoma, but no metastatic disease-related symptoms
- Primary: Sigmoïd
- Metastases: Multiple large bilobar synchronous livermetastases
Mutation status: Status unknown, insufficient tumor tissue available at the start of treatment
RS: NA BRAF: NA MSI: NA
- Young, fit patient who absolutely wants to preserve his professional and social engagement
- The extended liver involvement outweighs the urgency of primary tumor resection
Although extensive disease, aim for rapid response to achieve secondary resection and potential cure
Timeline with the key-moments
Avastin, approved nearly 15 years ago and reimbursed in Belgium for 10 years*, was the first-ever anti-angiogenic agent to offer a clinically meaningful survival benefit to 1st line metastatic colorectal cancer (mCRC) patients1,2.
Today, more than 3 million patients worldwide have been treated with Avastin in multiple cancer types.3
More related Patient Cases
Why did you select this patient case ?
This case demonstrates a good response on FOLFOX + Avastin in a left-sided RAS WT tumor, allowing secondary resection and long term (2 years) recurrence-free survival.
Applying a Stop & Go approach offered a long term disease control with preserving a good QoL in which both professional as social activities could be continued.
Would you take the same approach today ?
Today, I would have requested a second biopsy to include the molecular profile before starting systemic therapy
What message would you share with your colleagues?
Although this disease seemed initially unlikely to be resectable, reevaluation is crucial to achieve the best possible outcome.